Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Echis pyramidum* venom is a complex biological mixture derived from the Egyptian saw-scaled viper, currently under investigation for its potential as an antineoplastic agent. Research indicates that the venom possesses significant cytotoxic properties against various human cancer cell lines, most notably breast cancer (MCF-7) and hepatocellular carcinoma (HepG2). Its mechanism of action involves the induction of oxidative stress, evidenced by elevated levels of malondialdehyde (MDA) and alterations in glutathione (GSH) content, which leads to mitochondrial dysfunction and the activation of apoptotic pathways. Furthermore, the venom has been shown to cause genomic DNA damage and membrane disruption, as indicated by the release of lactate dehydrogenase (LDH). In vitro assays have demonstrated that the venom is particularly potent against breast cancer cells, with an IC50 value of approximately 3.48 μg/ml.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echis pyramidum venom.